Efficacy of dose escalation of imatinib mesylate in patients with cytogenetic or hematologic resistance [11]

Leukemia and Lymphoma

Volumn 48, Issue 8, 2007, Pages 1659-1661

  Sohn, Sang Kyun ^a   Moon, Joon Ho ^a   Cho, Yoon Young ^a   Chae, Yee Soo ^a   Kim, Jong Gwang ^a   Lee, Kun Soo ^a   Hong, Sun Pyo ^b   Kim, Soo Ok ^b  

^a Kyungpook National University Hospital   (South Korea)

^b AmorePacific Corporation   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; HYDROXYUREA; IMATINIB; INTERFERON; ISOLEUCINE; NILOTINIB; PHENYLALANINE; THREONINE;

ADULT; AGED; CANCER STAGING; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUTATIONAL ANALYSIS; PHILADELPHIA CHROMOSOME NEGATIVE CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34547979951     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701474381     Document Type: Letter

References (7)

1. Wang, L., Pearson, K., Pillitteri, L., Ferguson, J. E. and Clark, R. E. (2002) Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia. Br J Haematol, 118, pp. 771-777.
2. Hochhaus, A. and La Rosee, P. (2004) Imatinib therapy in chronic myelogenous leukemia: Strategies to avoid and overcome resistance. Leukemia, 18, pp. 1321-1331.
3. Kantarjian, H. M., Talpaz, M., O'Brien, S., Giles, F., Garcia-Manero, G. and Faderl, S. (2003) Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood, 101, pp. 473-475.
4. Marin, D., Goldman, J. M., Olavarria, E. and Apperley, J. F. (2003) Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. Blood, 102, pp. 2702-2703.
5. Hong, S. P., Kim, N. K., Hwang, S. G., Chung, J. H., Kim, S. and Han, J. H. (2004) Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments. J Hepatol, 40, pp. 837-844.
6. Kantarjian, H., Giles, F., Wunderle, L., Bhalla, K., O'Brien, S. and Wassmann, B. (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med, 354, pp. 2542-2551.
7. Zonder, J. A., Pemberton, P., Brandt, H., Mohamed, A. N. and Schiffer, C. A. (2003) The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clin Cancer Res, 9, pp. 2092-2097.